Skip to content

Inflammation in Tinnitus

The Role of Inflammation in the Pathogenesis of Tinnitus

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05268770
Acronym
INFLATIN
Enrollment
100
Registered
2022-03-07
Start date
2022-03-31
Completion date
2022-08-31
Last updated
2022-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammation, Tinnitus, Tinnitus, Subjective

Brief summary

Rationale: Tinnitus is the perception of sound without an external source. In the past decade, inflammation has been implicated in the pathophysiology of tinnitus. In animal models of tinnitus, the expression of proinflammatory cytokines Tumor Necrosis Factor-α (TNF-α) and interleukine-1β (IL-1β) was increased throughout the whole auditory tract. Only two studies evaluated cytokine concentrations in tinnitus patients. In these studies an increase of IL-6 and decrease of IL-10 have been objectified. However, studies did not include tinnitus patients based on the degree of hearing loss, despite that inflammation has also been implicated in hearing loss. On the other hand, studies about inflammation in hearing loss did not (always) exclude tinnitus. Thus, it remains unclear whether the upregulated cytokine concentrations the studies are specific for tinnitus, and whether potential effects remained unsignificant because the presence of hearing loss is a confounder. Therefore, the aim of this study is to evaluate the presence of inflammation in tinnitus patients with normal hearing. Objective: The main objective is to evaluate the presence of inflammation in blood samples of human subjects with tinnitus and normal hearing, compared to healthy controls. The secondary objective is to evaluate the relation between tinnitus severity and inflammatory marker concentrations. Study design: This is a cross-sectional study. Study population: Patients who have been referred to the tinnitus consultation at the outpatient clinic will be asked to participate in this study. For the control group, healthy volunteers will be recruited. Main study parameters/endpoints: The main study parameter is the disparity in blood cytokine levels between participants with and without tinnitus. Secondary study parameters are the relation between tinnitus severity and blood cytokine concentration, and the difference in complete blood count measures in participants with and without tinnitus.

Interventions

None listed

Sponsors

University Medical Center Groningen
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* To be eligible to participate in this study, a subject must meet all of the following criteria: * Adult, aged 18 years or older; * Hearing threshold: average of 1000kHz, 2000kHz & 4000kHz ≤ 25 dB. * Anxiety score HADS ≤ 7 * Depression score HADS ≤ 7 * Participant has sufficient mastery of the Dutch language to fill out the questionnaires. * Psychosocially, mentally, and physically able to fully comply with this protocol.

Exclusion criteria

* Objective tinnitus. * Presence of neurological disease (apart from tinnitus) * Presence of inflammatory disease, or the use of anti-inflammatory medication. * Presence or history of a malignancy * Presence of a disease of the ear (e.g. chronic otitis media, otosclerosis, previous surgery etc). * Presence of an coagulation disorder * Presence of a serious psychiatric disorder. * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Tinnitus vs no tinnitusSeptember 2022Difference in cytokine levels between participants with and without tinnitus

Secondary

MeasureTime frameDescription
Tinnitus severitySeptember 2022Relation between cytokine levels and tinnitus severity

Contacts

Primary ContactLilian M Mennink, MD
l.m.mennink@umcg.nl0031503610522

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026